Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.

Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.

Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2022
Current Issue: 2022  Archive: 2021 2020 2019 2018 2017

Special Issue

Unmet Need in the Management of Chronic Hepatitis C

Submission Deadline: January 31, 2020 (Open) Submit Now

Guest Editor

Chung-Feng Huang, MD,PhD

1. Associate Professor, Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
2. Faculty of Medicine and Hepatitis Research Center, College of Medicine, and Center for Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan

Website | E-Mail

Research Interests: Liver Diseases; Hepatocellular Carcinoma; Chronic Hepatitis C; Viral Hepatitis

About This Topic

Hepatitis C virus (HCV) infection is one of the major etiologies of liver cirrhosis and hepatocellular carcinoma worldwide. With the great innovation of directly acting antivirals, most patients with chronic hepatitis C (CHC) could be cured. However, there are several unmet needs to be solved. For example, the gap of HCV diagnosis and accessibility to medical care, difficult-to-cure populations including patients with liver decompensation, treatment-emergent variants and retreatment options, and long-term hepatic and extrahepatic outcomes in the post sustained virologic response (SVR) era. This special section seeks submissions for including but not restricted to abovementioned hot issues. The submissions can be in the form of review articles, opinions or original research. We would like to invite you to submit your work for consideration of publication in this special issue.


Open Access Review

Use of Organs from Hepatitis C Viremic Donors: Addressing the Needs of a Changing Waitlist and the Effect of a Public Health Crisis

Received: 14 May 2020;  Published: 20 July 2020;  doi: 10.21926/obm.hg.2003049


The combination of broad screening initiatives and development of effective antiviral therapies have led to a revolution in the treatment of hepatitis C virus and has reduced the proportion of patients with the virus who develop a need for liver transplantation in favor of other etiologies, such as alcohol-related liver disease and non-alcohol [...]
Open Access Review

Can HCV Viremic Organs Be Used in Liver Transplantation to HCV Negative Recipients?

Received: 02 February 2020;  Published: 24 April 2020;  doi: 10.21926/obm.hg.2002046


Liver transplantation has steadily increased worldwide resulting in a large number of patients on the waiting list. Due to the opioid epidemic in the US, the pool of Hepatitis C seropositive donors increased significantly in recent years. Direct acting antivirals played an instrumental role in making liver transplantation with hepatitis C [...]
Open Access Opinion

Vitamin D in Patients with Chronic Hepatitis C Virus Infection Receiving the Direct Antiviral Agents

Received: 23 February 2020;  Published: 30 March 2020;  doi: 10.21926/obm.hg.2001044
Open Access Original Research

The Daclatasvir/Asunaprevir/Beclabuvir Combination Therapy for Chronic Hepatitis C Patients Experiencing Failure of IFN-Free DAA-Based Therapies

Received: 29 September 2019;  Published: 17 December 2019;  doi: 10.21926/obm.hg.1904041


Background: Daclatasvir/asunaprevir/beclabuvir (DCV/ASV/BCV) combination therapy had been available for the treatment of chronic hepatitis C patients with genotype 1 (CHG1) in Japan. Our aim was to report the efficacy and safety of DCV/ASV/BCV in patients experiencing treatment failure with interferon (IFN)-free direct-acting antiviral agent [...]